MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Vikas Gupta, Marina Kremyanskaya et al.|Journal of Clinical Oncology|2023Cited by 89
S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDYJohn Mascarenhas, Vikas Gupta, Marina Kremyanskaya et al.|HemaSphere|2022Cited by 9
The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center ExperienceJudy Foster, Karen K. Ballen, Andrew M. Brunner et al.|Blood|2015Cited by 4